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Rationale
Aortic stenosis is the most common type of valve disease in the adults. Until recently its treatment was an exclusive domain of cardiac surgery. At the same time the aortic valve replacement (SAVR) was not indicated in about 1/3 of the patients [1] though the prognosis of conservatively treated patients is very unfavourable with one-year mortality rate of 50%. These facts were the main reasons for starting a new interventional era of the aortic valve disease therapy in 2002 [2] . From 2007 two new types of valves in stents have been commercially available-balloon expandable Edwards Sapian valve (Edwards Lifesciences, Inc., Irvine, California) and the selfexpanding CoreValve (Medtronic, Inc., Minnesota, USA) [3, 4] . If the standard femoral approach is impossible to use there are several alternatives like the transapical, transsubclavian, transaortic or recently described transcarotid approaches. On the contrary to SAVR the native severely diseased aortic valve remains in place enabling the new valve to reach a stable position. In the early phase the transcatheter aortic valve implantation (TAVI) was used just in patients with contraindication to SAVR or with high perioperative risk after surgery. In some countries the increased experience and good short-and middle-term results of TAVI resulted in broad application of TAVI nearly as equivalent to SAVR. Some problems have to be solved before general acception of such strategy: 1. What clinical impact will have the relative high rate of paravalvular leaks? and 2. What will be the function of the implanted valve in real long-term follow-up exceeding 5 years?
Besides the randomized trials comparing the TAVI vs. SAVR [5, 6] and several registries [7] [8] [9] it is important to get also our own national data. The Czech TAVI Registry comprises the use of both currently available types of valves and the results can help to answer the above mentioned and clinically relevant questions.
TAVI programme in the Czech Republic
In the Czech Republic the first TAVI was performed in Prague, IKEM in December 2008 [10] . During a short period of time the TAVI programme was initiated also in other complex cardiovascular centres in Hradec Kralove [11] , Brno [12] , Prague-FN Kralovske Vinohrady and Trinec. Including the later starting centres (Usti n. Labem, Olomouc, Ceske 
Czech TAVI Registry-dataset
The web-based Czech TAVI Registry has two main parts describing the hospital phase and follow-up of the patients at 1 month and yearly after the procedure. The total of 222 in-hospital parametres and 19 parametres during each follow-up are collected. Separate questionnaire has to be filled in if the patient dies. All the data are marked as Pending -Completed -Uncollectable.
General description of the Czech TAVI Registry can be found at http://www.registry.cz/index.php?pg=projekty& prid=60. Direct link to the database (http://tavi.registry.cz) is used by the investigators from participating centres.
Other national and international TAVI registries
There are several other national and international ongoing TAVI registries both in Europe and outside Europe, e.g., Belgian, Canadian, French, German, Italian, Israel, SOURCE, Swiss, UK, WIN TAVI Registries, STS/ACC TVT Registry and already mentioned European TCVT Pilot Registry. The high number of different TAVI registries and ongoing big trials (PARTNER 2, SURTAVI) may serve as a potent marker of the importance of TAVI. In relatively near future the optimal treatment strategy of patients with severe aortic stenoses might be changed and TAVI has the potential to do it.
Conclusion
Czech TAVI Registry is a nation-wide registry including more than 90% of all the Czech centres and about 95% of all the TAVI procedures performed in the Czech Republic. The first analyses with at least 1-year outcome of 250 patients will be completed in 2012.
